Biotech Values

[DonShimoda]

XOMA -- Poster for XOMA 052 (Gevokizumab) in Resistant Uveitis of Behçet’s Disease

Findings of this pilot trial suggest that IL-1ß plays a major role in Behcet's uveitis. Intraocular inflammation began to resolve in all 7 patients on Day 1, with a median time to first response of 4 days. Five out of 7 patients were in remission by Day 28. One patient, after a single infusion, remained in remission on Day 98. http://bit.ly/13a2zjF

Uveitis of Behçet’s Disease Pilot Trial Results http://bit.ly/Wfmg3k

Development of Immunopathogenesis Strategies to Treat Behçet's Disease
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3324914/